Burning Rock Biotech Ltd. ADR (BNR): Price and Financial Metrics
BNR Price/Volume Stats
| Current price | $2.73 | 52-week high | $4.24 |
| Prev. close | $2.66 | 52-week low | $1.70 |
| Day low | $2.62 | Volume | 47,000 |
| Day high | $2.90 | Avg. volume | 108,573 |
| 50-day MA | $2.87 | Dividend yield | N/A |
| 200-day MA | $2.78 | Market Cap | 287.16M |
BNR Stock Price Chart Interactive Chart >
BNR POWR Grades
- BNR scores best on the Sentiment dimension, with a Sentiment rank ahead of 86.48% of US stocks.
- BNR's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
- BNR ranks lowest in Momentum; there it ranks in the 6th percentile.
BNR Stock Summary
- For BNR, its debt to operating expenses ratio is greater than that reported by merely 9.01% of US equities we're observing.
- With a year-over-year growth in debt of -45.5%, BURNING ROCK BIOTECH LTD's debt growth rate surpasses just 6.5% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BNR comes in at 28.82% -- higher than that of 93.59% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to BURNING ROCK BIOTECH LTD are IGC, S, CHGG, AFRM, and ASAN.
- Visit BNR's SEC page to see the company's official filings. To visit the company's web site, go to www.brbiotech.com.
Burning Rock Biotech Ltd. ADR (BNR) Company Bio
Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The company operates through following segment: central laboratory business, in-hospital business and pharma research and development services. Its products and clinical applications including companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. Burning Rock Biotech was founded by Yu Sheng Han in 2014 and is headquartered in Guangzhou, China.
Latest BNR News From Around the Web
Below are the latest news stories about BURNING ROCK BIOTECH LTD that investors may wish to consider to help them evaluate BNR as an investment opportunity.
Burning Rock Provides First Quarter 2023 Business Updates and Schedules Earnings Release on May 30, 2023GUANGZHOU, China, April 27, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2023 before the U.S. market opens on May 30, 2023. Following the release, company management will host a conference call at 8:00 a.m. ET (8 |
Burning Rock Publishes 2022 Annual Report on Form 20-FGUANGZHOU, China, April 20, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 21, 2023 it filed its Annual Report on Form 20-F for the year ended December 31, 2022 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website |
Burning Rock Biotech Limited's (NASDAQ:BNR) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 3.7x Burning Rock Biotech Limited ( NASDAQ:BNR ) may be sending very bullish... |
Burning Rock Biotech Limited (NASDAQ:BNR) Q4 2022 Earnings Call TranscriptBurning Rock Biotech Limited (NASDAQ:BNR) Q4 2022 Earnings Call Transcript March 28, 2023 Operator: Before we begin, I’d like to remind you that this conference call contains forward-looking statements within the meaning of Section 21(e) of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act […] |
Burning Rock Reports Fourth Quarter and Full Year 2022 Financial ResultsGUANGZHOU, China, March 28, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2022. 2022 Business Overview and Recent Updates Corporate Listed on the Main Market of the London Stock Exchange (the “LSE”) by way of a direct listing |
BNR Price Returns
| 1-mo | -11.65% |
| 3-mo | -16.51% |
| 6-mo | 7.48% |
| 1-year | 13.75% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 21.33% |
| 2022 | -76.39% |
| 2021 | -58.74% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...